Antimanic Efficacy, Tolerability, and Acceptability of Clonazepam: A Systematic Review and Meta-Analysis.

J Clin Med · 2023 · PMC10531794 · PMID 37762742

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Lorazepam Data from the only study comparing Clonazepam with another benzodiazepine, namely Lorazepam [ 47 ], showed a trend for the superiority of Lorazepam over Clonazepam in terms of acute antimanic efficacy (14 days, monotherapy, SMD = 0.82, 95%CI = [−0.02, 1.67], p = 0.06, one RCT, N = 24).

also in 53,322 other papers

marginally significantno p-value reported

There was a trend for superiority of Lorazepam over Clonazepam acutely and the difference became marginally significant, in favor of Lorazepam, in the medium term (28 days, Figure S10 in Supplementary Materials ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.